Euroopan unioni - ruotsi - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidin - leukemi, myeloid, akut - antineoplastiska medel - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Euroopan unioni - ruotsi - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiska medel - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopan unioni - ruotsi - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiska medel - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Euroopan unioni - ruotsi - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanom - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Euroopan unioni - ruotsi - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - deucravacitinib - psoriasis - immunsuppressiva - treatment of moderate-to-severe plaque psoriasis in adults.

Euroopan unioni - ruotsi - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - andra hjärtpreparat - treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

bristol lab. ltd. - sumatriptansuccinat - filmdragerad tablett - 50 mg - laktosmonohydrat hjälpämne; sumatriptansuccinat 70,08 mg aktiv substans - sumatriptan

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

bristol-myers squibb ab - amfotericin b - sugtablett - 10 mg - amfotericin b 10 mg aktiv substans; mannitol hjälpämne - amfotericin b

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

bristol-myers squibb ab - buspironhydroklorid - tablett - 10 mg - laktos (vattenfri) hjälpämne; buspironhydroklorid 10 mg aktiv substans - buspiron

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

bristol-myers squibb ab - buspironhydroklorid - tablett - 15 mg - buspironhydroklorid 15 mg aktiv substans; laktos (vattenfri) hjälpämne - buspiron